Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial

BACKGROUND: With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome (SBS), there is emerging evidence that GLP-2 may play a role in the restoration of the disturbed homeostatic feedback in the gut-liver axis and may ameliorate SBS-associated liver damage. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Naimi, Rahim Mohammad, Hvistendahl, Mark, Nerup, Nikolaj, Ambrus, Rikard, Achiam, Michael Patrick, Svendsen, Lars Bo, Grønbæk, Henning, Møller, Holger Jon, Vilstrup, Hendrik, Steensberg, Adam, Jeppesen, Palle Bekker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710908/
https://www.ncbi.nlm.nih.gov/pubmed/31326433
http://dx.doi.org/10.1016/j.ebiom.2019.07.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710908/
https://www.ncbi.nlm.nih.gov/pubmed/31326433
http://dx.doi.org/10.1016/j.ebiom.2019.07.016

Ejemplares similares